GRANT OF OPTIONS

RNS Number : 1020D

Oncimmune Holdings PLC

24 April 2017

 

24 April 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

GRANT OF OPTIONS

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces that on 21 April 2017, options over 23,872 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to certain US staff under the Oncimmune Holdings Plc Incentive Stock Option Plan (as amended from the Oncimmune Limited Incentive Stock Option Plan that became effective 27 July 2009). The options are subject to the rules of the Incentive Stock Option Plan and vest in five equal annual parts, the first fifth vesting on 20 April 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 131 pence, being the mid-market closing price of the Ordinary Shares on 20 April 2017.

The Company also announces that on 21 April 2017, options over 30,534 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") were awarded to a member of UK staff under the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan. The options are subject to the rules of the Oncimmune Holdings Plc 2016 Unapproved & EMI Share Option Plan and vest in five equal annual parts, the first fifth vesting on 8 January 2018 and each year thereafter for a further four years, subject to continued employment. The options are exercisable at 131 pence, being the mid-market closing price of the Ordinary Shares on 20 April 2017.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Broker)

Phil Walker, Giles Balleny, Dominic Wilson

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

 

END

 

 

MSCGIGDSUBDBGRS